We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Multiplexed Immunoassay System Differentiates Malaria Species

By LabMedica International staff writers
Posted on 02 Oct 2019
Over 40% of world’s population live in malaria-endemic areas, and malaria is found in more than 100 countries in Africa, Latin America, the Caribbean, Southeast Asia, the Eastern Mediterranean, the Western Pacific, and parts of Europe.

Malaria continues to impose a tremendous burden in terms of global morbidity and mortality, yet even today, a large number of diagnoses are presumptive resulting in lack of or inappropriate treatment. More...
Early diagnosis and prompt, appropriate treatment is essential for improving patient outcomes, preventing overuse of malarial drugs, and minimizing development and spread of anti-malarial drug resistance.

Scientists from Cornell University (Ithaca, NY, USA) and their colleagues developed a two-color lateral flow immunoassay (LFA) system to identify infections by Plasmodium spp. and differentiate Plasmodium falciparum infection from the other three human malaria species (Plasmodium vivax, Plasmodium ovale, Plasmodium malariae). To validate the performance of the assay, 25 clinical research samples in whole blood form were tested: 15 malaria negative samples, five P. falciparum positive samples, and five P. vivax positive samples.

The assay performance was first optimized and evaluated with recombinant malarial proteins spiked in washing buffer at various concentrations from zero to 1,000 ng mL−1. The color profiles developed on the single test line were discriminated and quantified: color types corresponded to malaria protein species; color intensities represented protein concentration levels. The samples were also tested using commercially available ELISA kits: Quantimal pLDH CELISA, and Quantimal Pf-HRP2 CELISA to get quantitative results to evaluate the performance of the LFA strips.

The team reported that the limit of detection (the lowest concentrations of malaria antigens that can be distinguished from blank samples) and the limit of color discrimination (the limit to differentiate pLDH from PfHRP2) were defined for the two-color assay from the spiked buffer test, and the two limits were 31.2 ng mL−1 and 7.8 ng mL−1, respectively. To further validate the efficacy of the assay, the 25 human whole blood frozen samples were tested and successfully validated against ELISA and microscopy results: 15 samples showed malaria negative; five samples showed P. falciparum positive; five samples negative for P. falciparum, but contained other malaria species.

The authors concluded that the assay provides a simple method to quickly identify and differentiate infection by different malarial parasites at the point-of-need and overcome the physical limitations of traditional LFAs, improving the multiplexing potential for simultaneous detection of various biomarkers. The study was published on September 18, 2019, in the Malaria Journal.

Related Links:
Cornell University


New
Gold Member
Aspiration System
VACUSAFE
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.